OMERS ADMINISTRATION Corp Invests $7.75 Million in CVS Health Corporation $CVS

Key Points

• OMERS Administration Corp. acquired 74,907 CVS Health shares during the second quarter, valued at approximately $7.75 million. Institutional investors and hedge funds collectively own 80.66% of CVS stock.
• CVS reported quarterly earnings of $2.58 per share on $106.1 billion in revenue, beating analyst estimates and marking 7.3% year-over-year revenue growth. The company maintained fiscal 2026 EPS guidance of $7.90–$8.10.
• Analysts remain broadly positive, with 22 Buy ratings and two Holds, a “Moderate Buy” consensus, and an average price target of $107.17. CVS also pays a quarterly dividend of $0.665 per share, yielding approximately 2.8% annually.

OMERS ADMINISTRATION Corp purchased a new stake in CVS Health Corporation (NYSE:CVS - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 74,907 shares of the pharmacy operator's stock, valued at approximately $7,749,000.

Several other hedge funds also recently added to or reduced their stakes in the stock. Leigh Baldwin & CO. LLC acquired a new position in shares of CVS Health in the 2nd quarter valued at about $830,000. Osmosis Investment Management UK Ltd acquired a new stake in CVS Health during the second quarter worth about $6,979,000. Sanctuary Advisors LLC acquired a new position in CVS Health in the second quarter valued at approximately $18,769,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of CVS Health during the second quarter valued at approximately $120,995,000. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of CVS Health in the 2nd quarter worth approximately $3,155,000. 80.66% of the stock is owned by institutional investors and hedge funds.

CVS Health Trading Up 1.1%

CVS Health stock opened at $94.06 on Tuesday. The firm has a 50 day simple moving average of $101.88 and a 200-day simple moving average of $89.08. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a market capitalization of $120.31 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 0.85 and a beta of 0.61. CVS Health Corporation has a 12-month low of $69.51 and a 12-month high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last announced its earnings results on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping the consensus estimate of $1.87 by $0.71. The firm had revenue of $106.10 billion for the quarter, compared to analysts' expectations of $100.03 billion. CVS Health had a return on equity of 13.12% and a net margin of 1.18%.The firm's quarterly revenue was up 7.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.81 earnings per share. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. As a group, equities research analysts expect that CVS Health Corporation will post 8.02 EPS for the current fiscal year.

CVS Health Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health's payout ratio is presently 70.37%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent research reports. UBS Group raised their target price on CVS Health from $122.00 to $126.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Mizuho lifted their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Monday, June 8th. JPMorgan Chase & Co. upped their target price on shares of CVS Health from $111.00 to $118.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 12th. Barclays raised their price target on shares of CVS Health from $106.00 to $108.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Finally, Bank of America increased their price objective on CVS Health from $100.00 to $110.00 and gave the stock a "buy" rating in a report on Monday, June 22nd. Twenty-two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and an average price target of $107.17.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source